Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.
Asensus Surgical, Inc. (NYSE American: ASXC) is a trailblazing medical device company that enhances minimally invasive surgery through digital laparoscopy. The company's flagship product, the Senhance® Surgical System, is the first machine vision system used in robotic surgery. It leverages augmented intelligence, connectivity, and robotics to address clinical, cognitive, and economic challenges in surgery.
Headquartered in Research Triangle Park, North Carolina, Asensus Surgical focuses exclusively on the research, development, and sale of medical device robotics aimed at improving surgical outcomes. The company's cutting-edge technology includes the Intelligent Surgical Unit™ that brings augmented intelligence into the operating room. One of its latest innovations is the LUNA™ Surgical System, a next-generation robotic and instrument system under development.
Committed to global healthcare improvements, Asensus Surgical has expanded its reach with the Senhance System now available in the US, EU, Japan, Russia, and select other countries. The system has recently been adopted by Nagoya University Hospital in Japan, dedicated to pediatric procedures. This marks a significant milestone, as the Senhance System offers specialized instrumentation and advanced clinical intelligence, aimed at reducing invasiveness and increasing precision in pediatric surgery.
In a recent strategic move, Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG. This merger, valued at $0.35 per share, is anticipated to enhance KARL STORZ's portfolio and market presence, particularly in the robotic surgical market. The transaction has been unanimously approved by Asensus’ Board of Directors and is expected to close during the third quarter of 2024.
Asensus Surgical continues to be driven by collaboration and human ingenuity, striving to make surgery more accessible and predictable while delivering consistently superior outcomes. For more detailed information, visit www.asensus.com.
Asensus Surgical (ASXC) will release its Q1 2022 financial and operational results on May 4, 2022, post-market. A conference call is scheduled at 4:30 p.m. ET to discuss the results, which will also be available via webcast. The company focuses on digitizing surgery through its Senhance Surgical System and aims to enhance surgical outcomes with advanced technologies like machine vision and deep learning. The system is currently available for sale in the US, EU, Japan, and select countries.
Asensus Surgical (ASXC) reported a strong performance for Q4 2021, with revenues of $2.5 million, a 130% increase year-over-year. Full-year revenue reached $8.2 million, up 159% from 2020. The company performed over 2,100 procedures, a 44% growth, and initiated 10 Senhance Surgical Programs. Key regulatory milestones included FDA clearances for machine vision capabilities and articulating instruments. Despite a net loss of $15.9 million in Q4, Asensus maintains a solid cash position of approximately $135.8 million, positioning itself for continued growth and innovation in 2022.
Asensus Surgical, Inc. (AMEX: ASXC) will release its fourth quarter and fiscal year 2021 financial results on February 28, 2022, after market closure. A conference call to discuss these results will take place at 4:30 p.m. ET on the same day, providing an opportunity for investors and analysts to engage with the company's insights. Asensus Surgical focuses on Performance-Guided Surgery through its innovative Senhance Surgical System, enhancing surgical outcomes via digital technologies.
Asensus Surgical (AMEX: ASXC) reported significant growth in its preliminary 2021 year-end update. The company performed over 2,000 procedures globally, representing a 42% increase from 2020, and initiated 10 new Senhance Surgical Programs. Four regulatory clearances were achieved, including FDA 510(k) approvals and CE Mark for the Intelligent Surgical Unit. Cash holdings reached approximately $135.8 million as of December 31, 2021. Revenue is projected between $7.9 million and $8.3 million for the year, marking a growth of 147% to 159% over the previous year.
Asensus Surgical (NYSE American: ASXC) announced participation in two upcoming conferences. The 40th Annual J.P. Morgan Healthcare Conference will feature a virtual presentation on January 13, 2022, at 9:00 am ET. Additionally, the company will join the H.C. Wainwright Bioconnect 2022 Conference with a pre-recorded chat available from January 10, 2022, at 7:00 am ET. Both webcasts will be accessible on the investor relations page for 90 days.
Asensus aims to innovate surgical outcomes with its Senhance® Surgical System.
Asensus Surgical, Inc. (NYSE American: ASXC) has announced that RZD Medicine, based in Rostov-on-Don, Russia, has launched its Senhance Surgical System program after purchasing the robotic surgical platform. This marks the second hospital in Russia to adopt Senhance, which utilizes augmented intelligence for enhanced surgical performance. RZD Medicine aims to improve patient outcomes through this advanced technology, which allows for minimally invasive procedures and offers features such as 3D visualization and haptic feedback.
Asensus Surgical, Inc. has announced that Franklin Medical Center in Winnsboro, Louisiana, will lease and utilize the Senhance Surgical System, marking its entry as the 4th Senhance Hospital in Louisiana. The Senhance platform boasts augmented intelligence, enabling real-time intraoperative measurements and advanced features like haptic feedback and eye-tracking. Asensus aims to enhance surgical outcomes while reducing recovery burdens for patients as part of its Performance-Guided Surgery initiative.
Asensus Surgical (ASXC) reported a record 47% increase in procedures using its Senhance® Surgical Systems in Q3 2021, driven by growth in Europe and the U.S. The company initiated four new programs, with significant advancements following FDA clearance for expanded capabilities of the Intelligent Surgical Unit™. Revenue rose to $2.6 million from $0.8 million year-over-year, while the net loss increased to $16.1 million. Cash reserves stood at approximately $147.9 million. Asensus aims to continue expanding Senhance adoption and enhancing surgical capabilities.
Asensus Surgical, Inc. (ASXC) announced that Shinmatsudo Central General Hospital in Japan has agreed to lease the Senhance Surgical System, making it the 7th Senhance hospital in the country. This development follows a series of recent installations in Japan, reflecting Asensus' growth in the region. The Senhance system utilizes augmented intelligence for enhanced surgical outcomes, featuring advanced technologies like haptic feedback and eye-tracking. The partnership aims to improve surgical care and operational efficiency.
Asensus Surgical, Inc. (NYSE American: ASXC) will announce its third quarter 2021 financial and operational results on November 3, 2021, after market close. A conference call will commence at 4:30 p.m. ET the same day, with access via phone or a live audio webcast. The company focuses on enhancing surgical outcomes through its Performance-Guided Surgery™ initiative, utilizing the Senhance® Surgical System and Intelligent Surgical Unit™ (ISU™) technology. For more details, visit www.asensus.com.
FAQ
What is the current stock price of Asensus Surgical (ASXC)?
What is the market cap of Asensus Surgical (ASXC)?
What does Asensus Surgical, Inc. do?
Where is Asensus Surgical headquartered?
What is the Senhance® Surgical System?
What is the latest innovation from Asensus Surgical?
In which regions is the Senhance® Surgical System available?
Has Asensus Surgical recently partnered with any hospitals?
What is the merger agreement with KARL STORZ about?
When is the merger with KARL STORZ expected to close?
Will Asensus Surgical continue to be publicly traded after the merger?
How can I learn more about Asensus Surgical's products?
